Five Prime announces pre-clinical data of anti-CCR8 FPA157 program
Category: #healthcare  By Akshay Kedari  Date: 2020-11-13
  • share
  • Twitter
  • Facebook
  • LinkedIn

Five Prime announces pre-clinical data of anti-CCR8 FPA157 program

Five Prime Therapeutics, Inc. has recently revealed the 1st pre-clinical data of the anti-CCR8 FPA157 program. The pre-clinical results were presented at the SITC (Society for Immunotherapy of Cancer)’s 35th Anniversary Annual Meeting and Pre-Conference Programs. The company is known for developing and discovering innovative protein therapeutics to enhance the lives of patients suffering from serious diseases.

FPA157 is a monoclonal antibody that targets CCR8, which has been designed to enhance the ADCC (antibody-dependent cell-mediated cytotoxicity) as well as reduce the T-regulatory cell population in the tumor environment. Tregs can lower the level of anti-tumoral responses and function through various suppressive mechanisms. The antibody is a part of Five Prime’s immune-oncology antibody pipeline, which is under several IND-enabling studies.

The poster of the data, ‘Development of FPA157, an anti-CCR8 depleting antibody to preferentially eliminate the tumor-infiltrating T-regulatory (T-reg) cells’ was revealed in the late-breaker liver question & answer session. Important highlights from the poster include:

  • High restriction of CCR8 expression to Treg cells within the tumor
  • Demonstration of anti-CCR8 antibody treatment from the pre-clinical studies, which depletes the CCR8+ Tregs in tumor micro-environment while sparing the peripheral Treg subsets
  • Development of strong anti-tumor memory responses via anti-CCR8 treatment
  • Potent NK (natural killer) cell-dependent CCR8+ target cell killing by using FPA157

As per the statement made by VP of Research, Andrew Rankin, Ph.D., the pre-clinical date from the FPA157 program suggest that the selective regulatory T cell depletion within the tumor, without affecting the peripheral Tregs, can be a promising therapeutic pathway to pursue. The recent announcement marks the 1st information shared publicly by Five Prime about its CCR8 inhibitor antibody in its immune-oncology pipeline. The company has expressed its excitement at further examining the FPA157 potential in the clinic.

Two live Q&A sessions will be held on 11th November and 13th November, with the poster author, Associate Director of Immuno-Oncology Research, Edwina Naik Ph.D.

Source credit:

https://investor.fiveprime.com/news-releases/news-release-details/five-prime-presents-first-preclinical-data-anti-ccr8-antibody

 

About Author

Akshay Kedari    

Akshay Kedari

Akshay holds a Bachelor’s degree in computer engineering. Despite having a penchant for software development and the like, Akshay took to writing as a career owing to his passion for the field. Presently, Akshay writes articles for itresearchbrief.com and a few oth...

Read More>>

More News By Akshay Kedari

Biological E starts human trials of COVID-19 vaccine in India
Biological E starts human trials of COVID-19 vaccine in India
By Akshay Kedari

Biological E. Limited, an India-based vaccines and pharmaceutical company, has reportedly started ph...

Opear reveals 2 promotions to boost patients’ access to healthcare
Opear reveals 2 promotions to boost patients’ access to healthcare
By Akshay Kedari

Opear MD, a membership-based app, has reportedly announced two promotions to improve affordability a...

FDA extends Ryplazim BLA review period for Liminal Biosciences
FDA extends Ryplazim BLA review period for Liminal Biosciences
By Akshay Kedari

Clinical stage biopharmaceutical major, Liminal Biosciences Inc., has reportedly announced the exten...